Salmeterol 50 µg

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00821093

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-01-31End: 2009-10-31Updated: 2011-08-18

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00876694

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease (COPD)

Start: 2009-03-31End: 2010-10-31Updated: 2011-11-08

Related Papers

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.

2011-03-0169 citations